Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

  • Gemma Salvadó
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmö Lund University Lund Sweden
  • Rik Ossenkoppele
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmö Lund University Lund Sweden
  • Nicholas J Ashton
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
  • Thomas G Beach
    Banner Sun Health Research Institute Sun City AZ USA
  • Geidy E Serrano
    Banner Sun Health Research Institute Sun City AZ USA
  • Eric M Reiman
    Banner Alzheimer's Institute Arizona State University and University of Arizona Phoenix AZ USA
  • Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
  • Niklas Mattsson‐Carlgren
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmö Lund University Lund Sweden
  • Shorena Janelidze
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmö Lund University Lund Sweden
  • Kaj Blennow
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
  • Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmö Lund University Lund Sweden

書誌事項

公開日
2023-03-13
権利情報
  • http://creativecommons.org/licenses/by/4.0/
DOI
  • 10.15252/emmm.202217123
公開者
Springer Science and Business Media LLC

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p> Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates have not yet been fully determined. To investigate and compare independent associations between multiple plasma biomarkers (p‐tau181, p‐tau217, p‐tau231, Aβ42/40, GFAP, and NfL) and neuropathologic measures of amyloid and tau, we included 105 participants from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with antemortem plasma samples and a postmortem neuropathological exam, 48 of whom had longitudinal p‐tau217 and p‐tau181. When simultaneously including plaque and tangle loads, the Aβ42/40 ratio and p‐tau231 were only associated with plaques (ρ <jats:sub>Aβ42/40</jats:sub> [95%CI] = −0.53[−0.65, −0.35], ρ <jats:sub>p‐tau231</jats:sub> [95%CI] = 0.28[0.10, 0.43]), GFAP was only associated with tangles (ρ <jats:sub>GFAP</jats:sub> [95%CI] = 0.39[0.17, 0.57]), and p‐tau217 and p‐tau181 were associated with both plaques (ρ <jats:sub>p‐tau217</jats:sub> [95%CI] = 0.40[0.21, 0.56], ρ <jats:sub>p‐tau181</jats:sub> [95%CI] = 0.36[0.15, 0.50]) and tangles (ρ <jats:sub>p‐tau217</jats:sub> [95%CI] = 0.52[0.34, 0.66]; ρ <jats:sub>p‐tau181</jats:sub> [95%CI] = 0.36[0.17, 0.52]). A model combining p‐tau217 and the Aβ42/40 ratio showed the highest accuracy for predicting the presence of Alzheimer's disease neuropathological change (ADNC, AUC[95%CI] = 0.89[0.82, 0.96]) and plaque load ( <jats:italic>R</jats:italic> <jats:sup>2</jats:sup>  = 0.55), while p‐tau217 alone was optimal for predicting tangle load ( <jats:italic>R</jats:italic> <jats:sup>2</jats:sup>  = 0.45). Our results suggest that high‐performing assays of plasma p‐tau217 and Aβ42/40 might be an optimal combination to assess Alzheimer's‐related pathology <jats:italic>in vivo</jats:italic> . </jats:p>

収録刊行物

  • EMBO Molecular Medicine

    EMBO Molecular Medicine 15 (5), e17123-, 2023-03-13

    Springer Science and Business Media LLC

被引用文献 (5)*注記

もっと見る

問題の指摘

ページトップへ